PharmaCyte Biotech Inc (PMCB)
2.155
-0.02
(-0.99%)
USD |
NASDAQ |
May 10, 16:00
2.16
0.00 (0.00%)
After-Hours: 20:00
PharmaCyte Biotech Enterprise Value: -25.27M for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | -25.27M |
| May 08, 2024 | -25.41M |
| May 07, 2024 | -25.83M |
| May 06, 2024 | -25.49M |
| May 03, 2024 | -25.83M |
| May 02, 2024 | -25.41M |
| May 01, 2024 | -25.66M |
| April 30, 2024 | -25.75M |
| April 29, 2024 | -25.75M |
| April 26, 2024 | -25.83M |
| April 25, 2024 | -25.75M |
| April 24, 2024 | -25.07M |
| April 23, 2024 | -25.66M |
| April 22, 2024 | -24.90M |
| April 19, 2024 | -25.75M |
| April 18, 2024 | -25.07M |
| April 17, 2024 | -25.75M |
| April 16, 2024 | -25.49M |
| April 15, 2024 | -25.83M |
| April 12, 2024 | -24.82M |
| April 11, 2024 | -24.22M |
| April 10, 2024 | -24.56M |
| April 09, 2024 | -24.22M |
| April 08, 2024 | -23.46M |
| April 05, 2024 | -23.21M |
| Date | Value |
|---|---|
| April 04, 2024 | -22.36M |
| April 03, 2024 | -22.44M |
| April 02, 2024 | -22.70M |
| April 01, 2024 | -23.00M |
| March 28, 2024 | -23.63M |
| March 27, 2024 | -23.04M |
| March 26, 2024 | -23.04M |
| March 25, 2024 | -22.70M |
| March 22, 2024 | -23.04M |
| March 21, 2024 | -23.29M |
| March 20, 2024 | -23.55M |
| March 19, 2024 | -25.58M |
| March 18, 2024 | -26.68M |
| March 15, 2024 | -27.19M |
| March 14, 2024 | -26.31M |
| March 13, 2024 | -26.82M |
| March 12, 2024 | -26.90M |
| March 11, 2024 | -26.56M |
| March 08, 2024 | -26.14M |
| March 07, 2024 | -26.22M |
| March 06, 2024 | -26.39M |
| March 05, 2024 | -26.39M |
| March 04, 2024 | -26.22M |
| March 01, 2024 | -25.97M |
| February 29, 2024 | -25.80M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-47.06M
Minimum
Feb 24 2022
79.89M
Maximum
Jan 31 2020
4.364M
Average
-15.05M
Median
Enterprise Value Benchmarks
| CEL-SCI Corp | 78.27M |
| AIM ImmunoTech Inc | 9.406M |
| IGC Pharma Inc | 31.90M |
| NovaBay Pharmaceuticals Inc | 2.645M |
| Protalix BioTherapeutics Inc | 67.01M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.6195M |
| Total Expenses (Quarterly) | 1.869M |
| EPS Diluted (Quarterly) | -0.65 |
| Earnings Yield | -55.56% |
| Normalized Earnings Yield | -699.70 |